Next Article in Journal
Epstein-Barr Virus-Negative Aggressive Natural Killer-Cell Leukaemia with High P-Glycoprotein Activity and Phosphorylated Extracellular Signal-Regulated Protein Kinases 1 and 2
Previous Article in Journal
Non-Secretory Immunoglobulin E Myeloma Associated with Immunoglobulin G Monoclonal Gammopathy of Undetermined Significance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 4
Issue 3
10.4081/hr.2012.e14
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Combination of Cyclophosphamide, Etoposide, Carboplatin and Dexamethasone as a Salvage Regimen for Refractory Multiple Myeloma Patients: A Comparison with a Historical Control Group

by
Reza Safaee
1,
Ahmad Ahmadzadeh
1,*,
Ramezanali Sharifian
1,
Amirhossein Emami
1,
Mir Saeed Yekaninejad
2,
Mohammad Hossein Jalili
1 and
Armita Valizadeh
3
1
Hematology and Oncology Research Center, Vali-Asr Hospital, Tehran University of Medical Science, Tehran, Iran
2
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3
3Department of Anatomy, Ahwaz Jundishapur University of Medical Sciences, Ahwaz, Iran
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2012, 4(3), e14; https://doi.org/10.4081/hr.2012.e14
Submission received: 11 April 2012 / Revised: 29 May 2012 / Accepted: 12 June 2012 / Published: 11 July 2012

Abstract

The aim of this study was to design a regimen for refractory multiple myeloma with minimum complications to achieve a reasonable response. Fifteen patients with active multiple myeloma after at least two lines of conventional treatment underwent therapy with our regimen for two cycles. Disease activity was evaluated after the last cycle. Another 15 patients with refractory multiple myelomas that had previously received only supportive therapy and pain management formed a historical control group. The follow-up period was 12 months for each study group. Of the patients receiving therapy, 6.7% achieved a complete response and 26.7% a partial response; overall response rate was 33.3%. Stable disease was achieved in 46.7% and 20% of the patients had progressive disease. There was no treatment related mortality. The hazard rate of death was 0.73 lower in the intervention group than in the historical control group. In the historical control group, 60% had progressive disease and 40% had stable disease; approximately 40% of patients died during the 12-month follow up. Also, the severity of pain was significantly reduced in the intervention group (P = 0.033). Our chemotherapy regimen showed a reasonable response in end stage patients with multiple myeloma in terms of disease control, reducing bone pain and improving survival, in addition to reducing toxicity.
Keywords: multiple myeloma; cyclophosphamide; dexamethasone; etoposide; carboplatin multiple myeloma; cyclophosphamide; dexamethasone; etoposide; carboplatin

Share and Cite

MDPI and ACS Style

Safaee, R.; Ahmadzadeh, A.; Sharifian, R.; Emami, A.; Yekaninejad, M.S.; Jalili, M.H.; Valizadeh, A. Combination of Cyclophosphamide, Etoposide, Carboplatin and Dexamethasone as a Salvage Regimen for Refractory Multiple Myeloma Patients: A Comparison with a Historical Control Group. Hematol. Rep. 2012, 4, e14. https://doi.org/10.4081/hr.2012.e14

AMA Style

Safaee R, Ahmadzadeh A, Sharifian R, Emami A, Yekaninejad MS, Jalili MH, Valizadeh A. Combination of Cyclophosphamide, Etoposide, Carboplatin and Dexamethasone as a Salvage Regimen for Refractory Multiple Myeloma Patients: A Comparison with a Historical Control Group. Hematology Reports. 2012; 4(3):e14. https://doi.org/10.4081/hr.2012.e14

Chicago/Turabian Style

Safaee, Reza, Ahmad Ahmadzadeh, Ramezanali Sharifian, Amirhossein Emami, Mir Saeed Yekaninejad, Mohammad Hossein Jalili, and Armita Valizadeh. 2012. "Combination of Cyclophosphamide, Etoposide, Carboplatin and Dexamethasone as a Salvage Regimen for Refractory Multiple Myeloma Patients: A Comparison with a Historical Control Group" Hematology Reports 4, no. 3: e14. https://doi.org/10.4081/hr.2012.e14

APA Style

Safaee, R., Ahmadzadeh, A., Sharifian, R., Emami, A., Yekaninejad, M. S., Jalili, M. H., & Valizadeh, A. (2012). Combination of Cyclophosphamide, Etoposide, Carboplatin and Dexamethasone as a Salvage Regimen for Refractory Multiple Myeloma Patients: A Comparison with a Historical Control Group. Hematology Reports, 4(3), e14. https://doi.org/10.4081/hr.2012.e14

Article Metrics

Back to TopTop